Protection from disease by antigen-specific CD8 T-cells depends on their proper activation, with corresponding increase in T-cell frequency, effector and memory cell differentiation, and development of T-cell functions. Several properties of T-cells have been established as correlates of protection from infectious diseases. First, T-cells need to recognize cognate antigen efficiently [1] [2] [3] (i.e., have good ''functional avidity'') which is controlled by T-cell receptors (TCRs) and coreceptors. Second, the precursor frequency of antigen-specific T-cells plays a critical role. 4, 5 And third, protection requires functional competence of T-cells, which depends on intermediate-to-high functional avidity and additional parameters. Attempts for a more complete characterization of correlates of protection have focused on direct ex vivo functional profiling of T-cells. 6, 7 These studies have indicated that strong cytotoxic activity and production of multiple cytokines correlates with improved disease outcome. 8, 9 Mouse models have suggested that tumor immunity may rely on similar principles as immunity to pathogens. Functional avidity appears to be essential, as well as the capacity of T-cells to recognize naturally processed and presented tumor antigens. 10 Moreover, the precursor frequency of naïve T-cells plays a key role. 11 Finally, it is important that T-cells are competent for proliferation, cell survival, homing, effector functions and generation of immunological memory. 8, [12] [13] [14] Activation of protective CD8 T-cells is best achieved by infection with natural pathogens. Among the commercially available vaccines, only live vaccines (e.g., smallpox and yellow fever vaccines) are capable of inducing large numbers of pathogen-specific CD8 T-cells. 15 However, live vaccines are rarely available. As compared to natural infection, most synthetic vaccines and cancer vaccines induce much weaker CD8 T-cell responses which are often unable to contain or eradicate tumors. 16 Among the available low-dose synthetic vaccines, formulations with antigenic peptides, CpG and IFA induce the strongest human CD8 T-cell responses. 17, 18 CpG and IFA are also excellent adjuvants when using recombinant proteins instead of peptides, but CD8 T-cell responses are less potent. 19, 20 In the present study, we analyzed CD8 T-cell responses of melanoma patients in unprecedented detail ex vivo, after vaccination with a low dose vaccine composed of Melan-A/MART-1 peptide and CpG 7909 (PF-3512676), emulsified in IFA. We have previously shown that this formulation induced high numbers of tumor antigen-specific T-cells in 8 of 8 HLA-A2 pos patients, and that the majority of the induced T-cells have high functional avidity and efficiently recognize tumor cells. 17 Here we confirm these findings in 24 patients and provide the first demonstration of tumor-specific CD8 T-cells that are multifunctional in vivo.
Methods

Patients, study protocol and eligibility criteria
This prospective Phase I clinical study (ClinicalTrials.gov Identifier NCT00112229) was performed by the Ludwig Institute for Cancer Research and the Multidisciplinary Oncology Center, upon approval by IRBs, Swissmedic and the LICR Protocol Review Committee. A total of 29 patients were included, and 24 patients were evaluable for this study, based on the availability of complete data sets and sufficient lymphocytes allowing direct ex vivo analysis of T-cell function. HLA-A2 pos patients with histologically proven metastatic (stage III/IV) melanoma of the skin expressing Melan-A/ MART-1 (RT PCR or immuno-histochemistry) were included upon written informed consent. Inclusion criteria were: Karnofsky performance status of !70 %, normal CBC and kidney-liver function, no concomitant antitumor therapy or immunosuppressive drugs. Exclusion criteria were pregnancy, seropositivity for HIV-1 Ab or HBs Ag, uncontrolled bleeding, clinically significant autoimmune disease and symptomatic heart disease (NYHA III-IV). Study end points were toxicity and CD8 T-cell response. ) were cryopreserved in RPMI 1640, 40% FCS and 10% DMSO. Phycoerythrin-labeled HLA-A*0201/Melan-A/MART-1 A27L peptide [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (ELAGIGILTV) and HLA-A*0201/EBV lytic protein BMLF1 280-288 (GLCTLVAML) tetramers were prepared as descried. 17 Anti-CD8, -CD28 and anti-CCR7 mAbs were purchased from BD PharMingen (San Diego, CA), anti-CD45RA from Beckman Coulter, goat anti-rat IgG Ab (for indirect staining of CCR7; Caltag Laboratories). All tetramer and antibody batches were titrated to determine optimal reagent concentrations. For all functional studies, cells were kept overnight in RPMI 10% FCS at 37 C and 5% CO 2 . Before staining, CD8
Study treatment
pos T-cells were enriched using a MiniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany) resulting in >90% CD3 pos CD8 pos cells. Cells (10 6 ) were incubated with tetramers (1 lg ml À1 , 60 min, 4 C) and then with antibodies (30 min, 4 C). For intracellular assessment of cytokines, 10 6 MiniMACS purified CD8 pos T-cells were first prestained with PE-labeled tetramers for 30 min at 4 C. Without this prestaining, the visualization of antigen-specific T-cells would be inefficient due to TCR downregulation (Supporting Information Fig. 1 ), precluding comprehensive quantification of functional cells among antigen-specific T-cell populations. Then, they (4 Â 10 5 T-cells) were incubated with 2 Â 10 5 T2 cells at 37 C for 4 hr with or without 10 lM peptide (Melan-A/MART-1 ELAGIGILTV, or EBV GLCTLVAML) and anti-CD107a FITC (BD PharMingen), whereby 10 lg ml À1 Brefeldin A (Sigma, St. Louis, MO) was added for the last 3 hr, in culture medium consisting of IMDM supplemented with 0.55 mM Arg, 0.24 mM Asn, 1.5 mM Gln, and 8% pooled human A pos serum (''complete medium''). T2 cells were used because of their enhanced stimulatory capacity related to membrane expression of costimulatory molecules, and TAP deficiency resulting in high density of specific pMHC complexes after peptide loading. Subsequently, cells were stained at 4 C with PE-labeled tetramers, anti-CD8, anti-CD28 and anti-CD45RA antibodies. For dead cell exclusion, cells were stained with live/dead fixable dead cell violet stain (Molecular Probes/Invitrogen). Then, cells were permeabilized with 0.1% saponin at 4 C, washed, and stained for 40 min with anti-IFNc PE-Cy7 , anti-TNFa Table 1A ). *p < 0.05; **p < 0.01; *** p < 0.001; no symbol, not significant.
circulating CD8 pos T-cells. Geometrical mean fluorescence intensity (GMFI) was used to quantify TCR and CD8 expression levels. To compensate for day-to-day variations, the values were normalized based on the GMFI of tetramer-negative CD8 T-cells.
Detection of pSTAT1 and pSTAT5
PBMCs were stained first with tetramers for 30 min, washed and stained with anti-CD4 and anti-CD8 mAbs for 20 min. Cells were resuspended in RPMI 10% FCS and left for 1 hr at 37 C and 5% CO 2 . Then cells were stimulated for 15 min with either IL-2 (100 ng ml
À1
) and IL-15 (10 ng ml 
CD3 zeta chain analysis
CD8 T-cells were enriched using the CD8 MiniMACS system from Miltenyi. Isolated CD8 T-cells were stained first with tetramers for 30 min, washed and stained with anti-CD8 antibody for 20 min. To exclude dead cells, samples were incubated with live/dead fixable aqua stain (Invitrogen), followed by intracellular staining of CD3 zeta chain antibody/ CD247 (AbD serotech) in presence of 0.1% saponin. As control we used the corresponding IgG2a isotype antibody. Samples were washed and analyzed on the Gallios Flow cytometer.
Tetraphosphoflow assay
We developed a novel technique for ex vivo detection of pERK1/2 in antigen-specific T-cells. CD8 T-cells were enriched using the CD8 MiniMACS system from Miltenyi, followed by staining first with tetramers for 30 min, washing and staining with anti-CD8 antibody for 20 min. Cells were cultured in RPMI 10% FCS for 1 h at 37 C and 5% CO 2 . In the meantime, T2 stimulator cells were pulsed with 10 lM peptides for 1 hr, washed and resuspended in RPMI 10% FCS. CD8 T-cells were coincubated with T2 stimulator cells (after 1 min centrifugation) for 10 min, in absence or presence of IL-2 (100 ng ml
À1
). As controls, CD8 T-cells were incubated with unpulsed T2 cells, or with 80 nM PMA. Samples were fixed immediately with BD Cytofix fixation buffer for 15 min at 37 C and 5% CO 2 , washed and permeabilized with Perm Buffer III (BD Biosciences) for 30 min at 4 C. Samples were washed two times, resuspended in 20 ll staining buffer and 5 ll of BD Phosflow anti-ERK1/2 (pY202/ pY204) antibody were added for 30 min at room temparature. Samples were washed and analyzed on a Gallios Flow cytometer.
Data analysis and statistics
Analysis of coproduction of cytokines and degranulation in Figure 1e was performed with SPICE software version 5.1. 21 With the aim of ranking patients with respect the multifunctional T-cells, we calculated a ''functional T-cell score'' based on the four functions analyzed (IFNc, TNFa, IL-2 and CD107a). The formula was: score ¼ 1Â% cells with one function þ 2Â% cells with two functions þ 4Â% cells with three functions þ 8Â% cells with four functions. Statistical significance was assessed by the nonparametric Mann-Whitney test or the parametric student t test, where appropriate. p values less than 0.05 were considered significant. Box-andwhisker plot representations were designed with boxes indicating 25-75 percentiles, whiskers 10-90 percentiles, and horizontal bars and ''þ'' within the box median and mean values, respectively.
Results
Functionally competent tumor-specific T-cells induced by vaccination with peptide and CpG
Melanoma patients received monthly s.c. injections of Melan-A/MART-1 peptide [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and CpG, emulsified in IFA. This vaccine induced high frequencies of circulating Melan-A/ MART-1 specific T-cells 17 (hereafter called ''tumor-specific T-cells''). T-cell frequencies were very much higher than before vaccination, and also much higher (about 10Â) than in patients vaccinated with the same peptide without CpG (Fig. 1a and Ref. 17 ). To investigate the functional competence of T-cells, we performed multiparameter flow cytometry assays after 4 hr triggering with peptide, allowing simultaneous assessment of cytokine production and degranulation. Many tumor-specific T-cells were functionally competent, as they produced IFNc, TNFa and IL-2, and upregulated CD107a (LAMP-1), a marker for degranulation and cytotoxicity 8, 9 (Figs. 1b and 1c and Supporting Information Table  1A ). T-cell function was highly significantly increased as compared to T-cells from before vaccination, and after vaccination without CpG (Fig. 1b) . As a reference, we analyzed Tcells specific for the HLA-A2-restricted epitope GLCTLVAML derived from the EBV lytic protein BMLF1, and found relatively similar functional competence (Figs. 1c and 1d and Supporting Information Table 1B ). IFNc and IL-2 productions were similar, but degranulation and TNFa production were less frequent in tumor-than in virus-specific T-cells (Fig. 1d) . Interestingly, the function of EBV-specific T-cells was similar in patients and untreated healthy donors (Fig. 1d) , which was also revealed by the evaluation of cells with 0, 1, 2, 3 or all of the 4 functions analyzed (Fig. 1e) . Typical for CD8 T-cells, IL-2 was less frequently produced, which was the case in both tumor-and virus-specific T-cells.
With the aim to obtain a single numeric value characterizing the functional competence of each T-cell population, we calculated a ''functional T-cell score'' (described in Methods). Using this score, the data again showed enhanced T-cell function when CpG was added to the vaccine formulation (Fig. 2a) , confirming the results obtained for the four individual T-cell functions (Fig. 1b) . The scores also confirmed that EBV-specific T-cells were of similar functional competence in healthy controls and patients, whereas the tumor-specific T-cells were slightly inferior (Fig. 2b) . The individual patient data showed large interindividual differences, from strong to modest, and in one patient (LAU 936) even ''nonfunctional'' tumor-specific T-cells (Supporting Information Table 1 ). We analyzed patients without vs. with metastases at the time of T-cell analysis, and found that only the latter had lower scores of tumor-specific T-cells when compared to virus-specific T-cells (Fig. 2c) . Therefore, the overall slightly inferior functionality of tumor-as compared to EBV-specific T-cells (Fig. 1d) was likely due to the reduced function of tumor-specific T-cells from tumor bearing patients (Fig. 2c) . However, after CpG-based vaccination even these patients generated T-cells with highly significantly enhanced function as compared to before vaccination, and to patients after vaccination without CpG (Fig. 2d) . Finally, we analyzed the patient's clinical outcome, and found that disease-free survival was significantly increased in patients who had T-cells above the half maximal score (Fig. 2e) . The results for overall survival of patients pointed in the same direction, but the difference to patients with T-cells below the half maximal score did not reach statistical significance (Fig. 2f) .
Frequencies and percentages of CD28
neg Melan-A/MART-1
specific T-cells correlate with function
Strong CD8 T-cell responses are known to be associated with enhanced effector cell differentiation and function. 15 Not surprisingly, we found that patients exhibiting high percentages (>0.5%) of tumor-specific T-cells had significantly enhanced functions on a per T-cell basis, for CD107a, IFNc and TNFa. By contrast, IL-2 production was similar to patients reaching only lower (<0.5%) percentages of tumor-specific T-cells (Fig. 3a) . Effector cell differentiation can be assessed by changes of cell surface receptors. We have previously shown that most antigen-specific T-cells became CCR7 neg CD45RA-neg effector memory cells after vaccination with peptide and CpG. 17 More extended phenotyping revealed that variable proportions of vaccine responding T-cells were CD28 neg (Fig.  3b) which is characteristic for advanced differentiation of virus-specific CD8 T-cells. 22 This is not usually observed after T-cell vaccination, except after vaccination with peptide and CpG. When comparing patients with strong T-cell responses (>0.5% of tumor-specific cells) with those with weaker T-cell responses, we found that the former contained significantly higher proportions of CD28 neg cells (Fig. 3b) , which were more often positive for CD107a and IFNc, and a similar trend for TNFa (Fig. 3c) , confirming strong effector function for CD28 neg cells. Finally, we analyzed TCR and CD8 expression levels. As compared to CD28 pos cells, CD28 neg cells showed similar TCR but lower CD8 expression, possibly related to their enhanced function associated with more pronounced ''tuning'' via CD8 downregulation in vivo. Figs. 1b and 2c) . (e,f) Kaplan-Meier curves for disease-free survival (e) and overall survival (f) from patients with T-cells scoring equal or above vs. below 50% of the highest score reached (10 vs. 14 patients, respectively). The 50% max score was 181 (Supporting Information Table 1 ). *p < 0.05; **p < 0.01; ***p < 0.001; no symbol, not significant.
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After 4-hr triggering with peptide, we found significant downregulation, which was evident for both TCR and CD8, and similar for CD28 pos and CD28 neg T-cells (Fig. 3d ).
T-cell responses independent of patient age and gender
Previous studies have suggested that T-cell responses decline with age. 24 Because our study population varied largely with respect to patient age, it was possible to analyze its impact. However, we found no significant correlations with frequency of tumor-specific T-cells after vaccination with CpG, IFA and peptide. Similarly, we found no significant differences of Tcell function between younger and older individuals (Fig. 4) . Finally, patient gender did not correlate with frequency and function of tumor-specific T-cells (not shown).
Efficient phosphorylation of STAT1 and STAT5
Previous studies have shown that T-cells of cancer patients may have functional defects in cytokine signaling. 25, 26 Because STATs play a central role, 27 we analyzed STAT phosphorylation after 15-min stimulation with the commonc chain cytokines IL-2 and IL-15. Interestingly, tumorspecific T-cells after vaccination with CpG showed similar frequencies of STAT5(pY694) positive cells as EBV-specific cells (Figs. 5a and 5c ). Total CD8 T-cells from patients were slightly lower, and CD4 T-cells higher. As expected, this (Figs. 1a and 1b, 2a and 2d ), all data for tumor-specific T-cells in this article are from the 24 evaluable patients vaccinated with CpG. Although we attempted to also characterize T-cells from patients before vaccination or after vaccination without CpG, there were not enough tumor-specific T-cells available for performing all the functional assays used in this study. These restrictions apply also to most other studies of T-cell based therapy in humans. 28 Expression of CD3 zeta chain and phosphorylation of ERK1/2 T-cells from cancer patients have been suggested to express abnormally low levels of the CD3 zeta chain, 29 which was however not confirmed in another study. 30 We found similar intracellular CD3 zeta chain expression by total CD8 T-cells and tumor-and virus-specific T-cells (Figs. 6a and 6b) . In turn, the importance of the MAP kinase for T-cell responses is well known. 31 Therefore, we developed a novel ''tetraphosphoflow assay'' combining the known phosphoflow technology 32 with tetramers, allowing the identification of ERK1/2 (pY202/ pY204) positive cells. Ten minutes after stimulation with peptide, distinct populations of pERK1/2 pos T-cells were detected with remarkably bright staining (Figs. 6c and 6d ). Earlier and later time points showed lower percentages and intensities for pERK1/2 staining (data not shown). Both tumor-specific and EBV-specific T-cells were significantly more frequently pERK1/2 pos after stimulation with cognate peptide antigen as compared to unstimulated CD8 T-cells. Comparable results were obtained upon addition of IL-2; there was a trend for increased phosphorylation in EBV-specific T-cells which was however not significant. Control stimulation with PMA showed significantly higher percentages of pERK1/2 pos cells, likely due to its powerful triggering of multiple signaling pathways. Together, our data suggest efficient TCR signaling, consistent with the overall data showing functional competence of tumor-specific T-cells after peptide/CpG vaccination.
Discussion
Multifunctional cancer-specific human T-cells have been described previously, but after ten or more days of in vitro 
Tumor Immunology
stimulation. 33 In contrast, multifunctional virus-specific Tcells have been shown by direct ex vivo analyses. 34 With the latter approach, we show here multiple functions of human tumor-specific CD8 T-cells in most patients of our study. In disease-free patients, T-cell functions were comparable to virus-specific CD8 T-cells, suggesting protective potential. The present data are in agreement with our previous report 17 that vaccination with peptide, CpG and IFA induced higher CD8 T-cell numbers and more pronounced effector differentiation than vaccination with DNA, recombinant viral vectors, or peptides and proteins in vaccine formulations without CpG. 22 Following multiple booster vaccinations, T-cell responses were maintained at high levels over extended periods of time, confirming previous data on cancer-specific human CD8 Tcells. 35, 36 The functionality on a per T-cell basis was increased in patients with high T-cell frequencies, as observed previously in mice and humans. 35, 37 Moreover, high frequency T-cell populations exhibited high proportions of CD28 neg cells, which showed enhanced effector function as compared to CD28 pos cells (the latter including memory cells), indicating that CD28 neg populations are enriched for effector cells.
Strong and continued T-cell activity was associated with persistence of codominant clonotypes, which were not limited by replicative senescence or functional alterations ( 36 and manuscript in preparation). Thus, strong T-cell responses dominated by advanced differentiated CD28 neg T-cells may be highly functional and can persist over many years. 35, 36 It has been suggested that increased incidence of infection and cancer of elderly individuals may be related to functional T-cell deficiencies. 24 A recent mouse study indicated that the appropriate choice of state-of-the-art vaccine adjuvants may overcome such deficits. 38 Indeed, our findings of vigorous self/tumor-specific T-cell responses even in elderly patients confirm that adjuvants such as CpG successfully promote strong T-cell responses independent of age.
We analyzed STAT phosphorylation, since recent studies had demonstrated defective signaling upon stimulation with interferon 25 and with IL-2 26 in circulating total CD8 and CD4 T-cells from melanoma patients. In contrast, our data revealed similar STAT phosphorylation in tumor-and virusspecific T-cells. Furthermore, functional T-cell competence depends on intact TCR signaling, whereby the MAP kinase pathway plays a major role. 31 Our novel method allowing identification of pERK1/2 positive cells among antigen-specific T-cells revealed similar results in tumor-and virus-specific T-cells. Thus, after CpG based vaccination, these signaling events appear intact. However, direct comparison with antigen-specific T-cells from nonvaccinated cancer patients is still lacking, due to the limited availability of un-manipulated cells, i.e., cells that have not been cultured for days or weeks. Further technical improvements are necessary for comprehensive characterization of signaling pathways in small numbers of tumor-specific T-cells. In general, many more studies are required for understanding T-cell signaling, including its differences between humans and mice. 31 With regard to clinical results, we found that T-cell function correlated significantly with disease-free survival of patients. A trend was also found for overall survival, but without reaching statistical significance. However, our study was a Phase I clinical trial and not randomized, indicating that these findings represent preliminary evidence. Nevertheless, our data are compatible with the notion that functionally competent tumor-specific CD8 T-cells may be clinical meaningful.
Patients with massive tumor burden are less likely to respond to immunotherapy, 39 a notion that becomes increasingly acknowledged together with identification of various mechanisms used by tumors to suppress anti-tumor immune responses. [40] [41] [42] Therefore, immunotherapy may preferentially be successful in patients with minimal residual disease, after early diagnosis and/or after complete surgical tumor resection. Although the majority of our patients had functionally competent T-cells, CD8 T-cells showed tendencies of lower cytokine production and degranulation in patients bearing metastases as compared to disease-free patients. Future studies will focus on patient heterogeneity and identify mechanisms responsible for the impaired T-cell responses. [40] [41] [42] In this regard, more detailed characterization of immune cell function is necessary not only for circulating cells, but also for cells directly isolated from tumor tissue. These aims were beyond the scope of the present manuscript and require collection of large amounts of tumor tissue.
We have previously reported significantly different T-cell responses in patients after vaccination with the analog ELA-GIGILTV decapeptide as opposed to the natural EAAGI-GILTV decapeptide. The analog peptide induced frequencies of Melan-A/MART-1 specific T-cells that were about twice as high than vaccination with the natural peptide. In contrast, the natural peptide triggered T-cells with higher functional avidity TCRs and enhanced IFNc production. 43 However, a minority of patients responded only very weakly to the natural peptide. In this study, 10/24 patients were vaccinated with the natural, and 14/24 patients with the analog peptide (Supporting Information Table 1A ). It was important to determine whether T-cell function depended on vaccination with natural vs. analog peptide. However, this was not the case, since degranulation and cytokine production were similar in the two patient groups (Supporting Information Table 1A ).
This was not surprising, since functional testing by triggering the T-cells with the analog Melan-A peptide does not reveal significant differences, whereas testing with natural peptide demonstrates superior functionality after vaccination with natural as opposed to analog vaccination. 43 In this study we used the analog peptide for functional testing because of the increased peptide/MHC stability important for assay reproducibility. Unfortunately, analyzing all patients and samples in all functional assays with both analog and natural peptide was not possible due to the limited availability of cells. Therefore, we currently develop novel molecular and functional assays allowing the reliable assessment of T-cell function with small cell numbers. These assays will be applied for all patients with available cells. Thus, it remains to be determined whether vaccination with the natural peptide results in superior T-cell function beyond the known enhanced IFNc production. 43 The natural and analog peptides represent very highly cross-reactive epitopes compatible with the similar configuration of the two peptide/MHC complexes. 44 We generated >1,000 T-cell clones, and did not find a single clone binding tetramers constructed with one but not the other peptide/ MHC complex. 43, 45 Similarly, cross-reactivity was always observed in functional assays, despite the quantitative differences found in peptide titration studies, with enhanced recognition of target cells labeled with natural peptide by T-cells from patients after vaccination with natural peptide. 43 Nevertheless, this system reveals a very high degree of cross-reactivity to self/tumor antigen. The characterization of fine differences of T-cell receptors and T-cell function after vaccination with natural vs. analog peptide remains challenging, 45 but is important in order to determine whether analog peptide vaccination remains an option in patients not responding to the natural peptide, or for enhanced boosting after priming with natural peptide.
Our findings of functionally competent self/tumor-specific T-cells are in disagreement with results showing that mechanisms of self-tolerance may impair T-cell function. 46, 47 T-cells with high affinity TCRs to self are eliminated in the thymus, which is likely also happening to some Melan-A/MART-1 specific T-cells, 35 resulting in deficiency of high affinity TCRs. We continue to study the TCR repertoires of human cancer-specific T-cells; including the concern that immunotherapy may activate low affinity T-cells that are unable to recognize naturally presented antigen. However, the majority of T-cells analyzed in this study have competent TCRs capable to recognize tumor cells. 43 Furthermore, recent studies suggest that low/intermediate avidity T-cells may have protective potential. 48 Many studies have shown that T-cells may be tolerized in the periphery, 49 e.g., by mechanisms of anergy and/or deletion of self-specific T-cells. Very recently, we demonstrated that circulating Melan-A/MART-1 specific Tcells had a gene expression profile of functional effector cells after vaccination with CpG, which was largely different in melanoma metastases where they showed significant molecular hallmarks of exhausted cells. 50 In contrast, after vaccination without CpG or in absence of immunotherapy, T-cells were poorly functional. Thus, self/tumor-specific Tcells may be functionally deficient due to insufficient T-cell stimulation, which is unfortunately the case for the majority of human T-cell vaccines, hence the need for improvement to achieve therapeutic efficacy. 15 Our data provide the rational basis for Phase III clinical trials with efficient T-cell vaccines, with the aim to determine whether this type of immunotherapy is indeed capable of improving clinical outcomes.
